$4.8 billion biotech Spark Therapeutics had to find a way to prove its first-of-its-kind treatment for eye disease actually worked. We got the inside story on how it pulled it off.
The biotech Spark Therapeutics needed a way to measure improvements to a patient's quality of life when testing a new treatment for a rare eye disorder. So Spark created a maze-like course, which included simulated obstacles like holes and grass, for use in key research. We spoke with Dan Chung, the clinical ophthalmic lead at Spark, about the company's efforts to do that in a rigorous and standardized way. Spark's treatment was approved in the US in late 2017. The one-time therapy is called Luxturna and has a list price of $850,000. And Spark agreed to be acquired by... [Read More]